Recent News

Antibody Response in Patients With CLL Following COVID-19 Vaccination

CLL–International Prognostic Index in Predicting Cause of Death in Newly Diagnosed CLL

Predicting Response to COVID-19 Vaccine in Patients With CLL

Emerging Targeted Therapies Under Study in CLL

SOHO 2021: How Does Acalabrutinib Measure Up Against Ibrutinib in CLL?

SOHO 2021: Early-Phase Results With Novel BTK Inhibitor in CLL

SOHO 2021: Understanding Clinical Outcomes in Patients With CLL Older Than 80

SOHO 2021: Case-Based Look at First-Line Therapy for Younger Patients With CLL

SOHO 2021: Can the Natural History of Immune Dysfunction and Infections in CLL Be Altered?

COVID-19 in Patients With CLL: Is Neutropenia a Risk Factor?

Predicting Survival in Patients With CLL: Focus on TP53 Mutations

Statin Use in Patients With CLL: Impact on Survival Outcomes

Can the NOTCH Network Be Used to Refine Risk Stratification in CLL?

Karyotypic Complexity and Evolution May Impact Survival of Ibrutinib-Treated Patients With CLL

Managing CLL During the COVID-19 Pandemic: An Italian Report

Incidence of Neutropenia With Venetoclax and Obinutuzumab in CLL

How Does Acalabrutinib Measure Up Against Ibrutinib in CLL in Phase III Trial?

Case Study: Autoimmune Hemolytic Anemia in Male Patient With CLL

Ibrutinib Plus Venetoclax in CLL: Oral Nonchemotherapy Regimen Under Study

Cohort Study of CLL and Leukemia Cutis From the French Innovative Leukemia Organization

Retrospective Look at Therapeutic Considerations for Adolescent and Young Adults With CLL

Multi-hit TP53-Aberrant CLL: Focus on Prognostication and Management

Can Baseline Geriatric Domains Help to Identify High-Risk Patients With CLL?

Novel BCL2 Inhibitor Under Study in Resistant CLL and Other Blood Cancers

Antibody Response to COVID-19 Vaccine in Patients With CLL

EHA2021: CLL14 Follow-up Supports Use of Venetoclax Plus Obinutuzumab

ASCO 2021: Converting Peripheral Blood Mononuclear Cells Into Autologous Cellular Therapy for CLL

What Next? Update on Management of Resistant CLL After First-Line Therapy

EHA2021: CLL14 Follow-up Supports Use of Venetoclax Plus Obinutuzumab

ASCO 2021: 4-Year Update of ELEVATE-TN Trial of Acalabrutinib Regimens in CLL

EHA2021: ALPINE Trial of Zanubrutinib Versus Ibrutinib in Resistant CLL

EHA2021: Phase III GLOW Trial of Ibrutinib and Venetoclax as First-Line CLL Therapy

ASCO 2021: Fixed-Duration Treatment With Ibrutinib Plus Venetoclax in CLL

ASCO 2021: Phase III Noninferiority Trial of Acalabrutinib Versus Ibrutinib in CLL

Richter’s Transformation in CLL: B-Cell Receptor Signals and Genetic Lesions

Impact of Ibrutinib on T-Cell Responses in CLL

Rare Case of Metastatic CLL Presenting as Focal Mass in the Gallbladder

Deletion 17p Subclones and Outcomes in Patients With CLL

FDA Brief: New Drug Application Accepted for CD20-Targeted CAR T-Cell Therapy for CLL

Genetic Relationship Between CLL and Non-Melanoma Skin Cancer?

Does Ibrutinib Therapy Induce Host Antitumor Immune Activation in CLL?

Potential Biomarkers in CLL Harboring Trisomy 12 Under Study

Case Study: Rare Richter Transformation of CLL Involving the Ear

Untangling Neutrophil Clues to Increased Bacterial Infections in CLL

Serum APRIL Levels: Novel Prognostic Marker Under Study in CLL